doi:10.3969/j.issn.1004-583X.2024.07.015

Abstract

CLC Number:

R735

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2024.07.015

https://huicui.hebmu.edu.cn/EN/Y2024/V39/I7/664

References 26

[1]	Mizrahi J, Pant S. Immunotherapy in Gastrointestinal Malignancies[J]. Adv Exp Med Biol, 2020, 1244:93-106. doi: 10.1007/978-3-030-41008-7_5 pmid: 32301012
[2]	王昱欢, 吴穹, 马晓峰, 等. 氧化三甲胺在动脉粥样硬化中的研究进展[J]. 中国动脉硬化杂志, 2023, 31(10):901-908.
[3]	Li CY, Chen XL, Zhang D, et al. Structural mechanism for bacterial oxidation of oceanic trimethylamine into trimethylamine N-oxide[J]. Mol Microbiol, 2017, 103(6):992-1003.
[4]	刘恺闻, 张魁, 周宁, 等. 肠道菌群与冠心病关系的研究进展[J]. 中国胸心血管外科临床杂志, 2023, 30(5):746-752.
[5]	Gatarek P, Kaluzna-Czaplinska J. Trimethylamine N-oxide (TMAO) in human health[J]. EXCLI J, 2021, 20:301-319. doi: 10.17179/excli2020-3239 pmid: 33746664
[6]	Fennema D, Phillips IR, Shephard EA. Trimethylamine and trimethylamine N-oxide, a flavin-containing monooxygenase 3 (FMO3)-mediated host-microbiome metabolic axis implicated in health and disease[J]. Drug Metab Dispos, 2016, 44(11):1839-1850. pmid: 27190056
[7]	Zhu Y, Li Q, Jiang H. Gut microbiota in atherosclerosis: focus on trimethylamine N-oxide[J]. APMIS, 2020, 128(5):353-366. doi: 10.1111/apm.13038 pmid: 32108960
[8]	宫铭, 张成普. 氧化三甲胺与老年常见恶性肿瘤关系的研究进展[J]. 实用老年医学, 2022, 36(1):14-18.
[9]	敦泽, 郭立芳. 幽门螺杆菌致病机制的研究进展[J]. 中国中西医结合消化杂志, 2020, 28(8):645-648.
[10]	Tacconi E, Palma G, De Biase D, et al. Microbiota effect on trimethylamine N-Oxide production: From Cancer to Fitness-a practical preventing recommendation and therapies[J]. Nutrients, 2023, 15(3):563.
[11]	Stonans I, Kuzmina J, Polaka I, et al. The association of circulating L-carnitine, gamma-butyrobetaine and trimethylamine N-oxide levels with gastric cancer[J]. Diagnostics (Basel), 2023, 13(7):1341.
[12]	Jalandra R, Dalal N, Yadav AK, et al. Emerging role of trimethylamine-N-oxide (TMAO) in colorectal cancer[J]. Appl Microbiol Biotechnol, 2021, 105(20):7651-7660.
[13]	Bardel̆cíková A, Šoltys J, Mojžiš J. Oxidative stress, inflammation and colorectal cancer: An overview[J]. Antioxidants (Basel), 2023, 12(4):901.
[14]	Yue C, Yang X, Li J, et al. Trimethylamine N-oxide prime NLRP3 inflammasome via inhibiting ATG16L1-induced autophagy in colonic epithelial cells[J]. Biochem Biophys Res Commun, 2017, 490(2):541-551.
[15]	Ke Y, Li D, Zhao M, et al. Gut flora-dependent metabolite trimethylamine-N-oxide accelerates endothelial cell senescence and vascular aging through oxidative stress[J]. Free Radic Biol Med, 2018, 116:88-100.
[16]	Man A, Zhou Y, Xia N, et al. Involvement of gut microbiota, microbial metabolites and interaction with polyphenol in host immunometabolism[J]. Nutrients, 2020, 12(10):3054.
[17]	Tarashi S, Siadat SD, Ahmadi BS, et al. Gut Bacteria and their metabolites: Which one is the defendant for colorectal cancer?[J]. Microorganisms, 2019, 7(11):561.
[18]	Drapala A, Szudzik M, Chabowski D, et al. Heart failure disturbs gut-blood barrier and increases plasma trimethylamine, a toxic bacterial metabolite[J]. Int J Mol Sci, 2020, 21(17):6161.
[19]	Sanchez-Alcoholado L, Ordonez R, Otero A, et al. Gut microbiota-mediated inflammation and gut permeability in patients with obesity and colorectal cancer[J]. Int J Mol Sci, 2020, 21(18):6782.
[20]	Yang S, Dai H, Lu Y, et al. Trimethylamine N-Oxide Promotes Cell Proliferation and Angiogenesis in Colorectal Cancer[J]. J Immunol Res, 2022, 2022:7043856.
[21]	Bhat MY, Singh LR, Dar TA. Trimethylamine N-oxide abolishes the chaperone activity of alpha-casein: An intrinsically disordered protein[J]. Sci Rep, 2017, 7(1):6572.
[22]	刘燕娥. 肠道菌群和氧化三甲胺与原发性肝癌的关系研究[D]. 长春: 吉林大学, 2023.
[23]	Cox IJ, Aliev AE, Crossey MM, et al. Urinary nuclear magnetic resonance spectroscopy of a Bangladeshi cohort with hepatitis-B hepatocellular carcinoma: A biomarker corroboration study[J]. World J Gastroenterol, 2016, 22(16):4191-4200.
[24]	Yang S, Li X, Yang F, et al. Gut microbiota-dependent marker TMAO in promoting cardiovascular disease: Inflammation mechanism, clinical prognostic, and potential as a therapeutic target[J]. Front Pharmacol, 2019, 10:1360. doi: 10.3389/fphar.2019.01360 pmid: 31803054
[25]	Huang JY, Luu HN, Butler LM, et al. A prospective evaluation of serum methionine-related metabolites in relation to pancreatic cancer risk in two prospective cohort studies[J]. Int J Cancer, 2020, 147(7):1917-1927. doi: 10.1002/ijc.32994 pmid: 32222976
[26]	Mirji G, Worth A, Bhat SA, et al. The microbiome-derived metabolite TMAO drives immune activation and boosts responses to immune checkpoint blockade in pancreatic cancer[J]. Sci Immunol, 2022, 7(75):eabn704.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 26

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	. [J]. Clinical Focus, 2024, 39(6): 563-567.
[2]	Wu Xiaomin, Fang Yipeng, Zhang Zhen, Zhang Ye, Jin Cheng. Clinical application of GEMOX combined with target-immunity therapy in patients with advanced biliary tract cancer [J]. Clinical Focus, 2024, 39(5): 408-412.
[3]	Zhao Xuhui, Huang Xiaomin, Da Dezhuan, Xu Yan, Cui Xiaodong, Li Hongling. Screening of glycolysis-related genes for predicting the prognosis of patients with gastric cancer: Based on bioinformatics [J]. Clinical Focus, 2024, 39(1): 20-29.
[4]	Zhu Chenglou, Wu Qiong, Da Mingxu. Risk assessment of pancreatic cancer in patients with type 2 diabetes mellitus treated with sitagliptin: A meta-analysis of randomized controlled trials [J]. Clinical Focus, 2023, 38(12): 1061-1066.
[5]	Wang Junhong, Gao Zhenhua, Zhang Ronglong, Ji Haomin, Zhao Xinke, Da Mingxu. Quality analysis of the literatures associated with gastric cancer diagnosis from 1980-2021——A bibliometric analysis based on the Web of Science database [J]. Clinical Focus, 2023, 38(12): 1117-1124.
[6]	. [J]. Clinical Focus, 2023, 38(11): 1048-1052.
[7]	Lyu Chang, Zhou Liming. Correlation between the TNF-α-308 gene polymorphism and gastric cancer susceptibility: A meta-analysis [J]. Clinical Focus, 2023, 38(9): 779-787.
[8]	You Yi, Gao Shuqing, Xu Hao. Effect of enteral nutrition on postoperative clinical outcome of esophageal neoplasms: A meta-analysis [J]. Clinical Focus, 2023, 38(6): 485-492.
[9]	Li Ya, Du Taoming, Qiu Shixiang, Chen Chao, Zhong Liming. Study on brain functional connectivity in patients with liver cancer with depression [J]. Clinical Focus, 2023, 38(6): 532-536.
[10]	Wang Yingnan, Zhao Qi, Bai Haiwei, Wu Danna, Wei Jinmei, Li Shengjiang, Li Ruiling, Zhang Ruixing. Clinical characteristics and risk factors of gastric cancer-related stroke [J]. Clinical Focus, 2023, 38(5): 417-422.
[11]	. [J]. Clinical Focus, 2023, 38(5): 473-476.
[12]	Shi Yujuan, Wang Jing, Xu Ping. Comparative analysis on pathological results of preoperative & postoperative colorectal intraepithelial neoplasia and early colorectal cancer endoscopic therapies [J]. Clinical Focus, 2023, 38(1): 55-59.
[13]	Zhang Yiming, Li Mingzhao, Gu Xin. Clinicopathological analysis of colorectal mixed adeno-neuroendocrine carcinoma: 8 cases report [J]. Clinical Focus, 2022, 37(10): 921-926.
[14]	Wang Chengyao, Zhang Zheng, Wu Jing. Meta analysis on correlation between sporadic duodenal neoplasm and colorectal neoplasm [J]. Clinical Focus, 2022, 37(7): 581-590.
[15]	Li Ya, Qiu Shixiang, Chen Chao, Zhong Liming. Depression-related factors and corresponding correlations with quality of life in patients with hepatocellular carcinoma [J]. Clinical Focus, 2022, 37(6): 539-543.